Endoscopic endgame for obstructive pancreatopathy: outcomes of anterograde EUS-guided pancreatic duct drainage. A dual-center study - 06/11/20
Abstract |
Background and Aims |
Anterograde endoscopic ultrasound-guided pancreatic duct drainage (EUS-PDD) refers to transmural drainage of the main pancreatic duct via an endoprosthesis passed anterograde through the gastric (or intestinal) wall. Anterograde EUS-PDD is a rescue procedure for recalcitrant cases of benign obstructive pancreatopathy.
Methods |
We conducted a dual-center retrospective chart review of 28 patients (mean age, 59 years; 50% female) who underwent attempted anterograde EUS-PDD between April 2016 and September 2019 for chronic pancreatitis (CP) (93%) or pancreaticojejunostomy stenosis (PJS) after Whipple resection (7%). The study endpoint was achievement of transpapillary/transanastomotic drainage (definitive therapy).
Results |
Gastropancreaticoenterostomy (ring drainage, definitive therapy) was successfully performed during the index procedure in the 2 patients with PJS (technical success, 100%). Clinical success was 100% in the 2 ring drainage recipients during a mean 18-month follow-up period. The remaining 26 patients with CP underwent attempted pancreaticogastrostomy (PG) with 81% technical success, 75% clinical success, and 15% adverse events (AEs). Repeat endoscopic transmural interventions were performed in the 15 patients with clinical success after PG creation. Definitive therapy transpired in all 15 patients after a median 1 repeat procedure per patient. Clinical success after definitive therapy was maintained in all 15 patients (100%) during a median 4.5-month follow-up.
Conclusions |
In agreement with previous studies, our study showed mild to moderately high rates of technical failure (19%), clinical failure (25%), and AEs (15%) during index drainage (PG creation). Among patients with CP with both technical and clinical success after index PG creation (n = 15), 100% definitive therapy was achieved and clinical outcomes were excellent (100% clinical success, 0% AEs).
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Abbreviations : AE, CP, EA-ERP, ECE-LAMS, ERP, EUS-PDD, IQR, MPD, PG, PJS, TMP-EHL
Plan
| If you would like to chat with an author of this article, you may contact Dr Krafft at mrkrafft@hsc.wvu.edu. |
|
| DISCLOSURE: Dr James receives research and training support in part by a grant from the NIH (T32DK007634). Dr Baron has done consultancy work for Boston Scientific, Cook Endoscopy, W.L. Gore, and Olympus America. Dr Nasr is a consultant for Boston Scientific. All other authors disclosed no financial relationships relevant to this publication. |
|
| See CME section; p. 1122. |
Vol 92 - N° 5
P. 1055-1066 - novembre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
